The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Yup, the regenerative shock absorbers were never part of the core proposition of guident . They saw an opportunity so acquired the patent.
The earnings potential for the shock absorbers could be tremendous .....or may not take off (or perhaps guident can enhance the technology and then it will be commercialised).
The core guident proposition remains solid.
Hopefully some good news coming
GLA
Hi D.monies,
Am not an expert on this technology but to the best of my knowledge neither examples you have provided relate to the guident low latency proposition.
1) a self parking car is just using sensors .
2) self autonomous cars can operate through through using their cameras and sensors and satellite navigation systems I.e. they are not being controlled in real time by an external source (or even necessarily receiving live/updated instructions from an external controller).
The low latency technology means a human driver can take control of the vehicle in certain situations- i.e difficult terrain or in the aftermath of an accident.
To have live control of a vehicle (as demonstrated in the video) requires minimal (safe level) latency (delay ) between the external operator/driver and the moving vehicle. Obviously any delay in the connectivity could have deadly consequences.
This is where guident distinguishes itself . It has produced patented low latency technology . Remember it is all about safety and the perceived level of safety (a high percentage of consumers believe autonomous vehicles are unsafe ). Guident is making huge progress in addressing these concerns.
Additionally , guident technology can be rolled out to control a fleet of autonomous vehicles or drones .....again all possible with the low latency technology ....making it possible to “communicate” with all individual vehicles simultaneously (safely).
We all have a view but the examples you are providing are not relevant IMHO . Not digging you out personally but trying to keep some kind of balance on here .
I do agree that not a great video from a marketing perspective but there is more to it than meets the eye .
As for the current share price , if you can’t convince financial institutions that the shares are worth more than 10p, it’s not totally surprising the wider market is now reflecting a similar valuation . I was disappointed at the placement but won’t harp on.
TEK is making progress but needs some good news to boast the share price ! That video certainly won’t be sending the SP upwards
There is no context around this video so could appear a bit lame .
But, while not being an expert, I know part of the guident proposition is the “low latency technology” which enables the car to controlled (remotely) safely and reliably.
What I am saying , is that the sophisticated technology underpinning what you are seeing is not evident from just seeing what looks like a remote control car !!
Guident is award winning and cutting edge , though not a great video !!
Bought yesterday and again today (despite be disappointed with the 10p placing).
Unfortunately, I now have slightly more TEK shares as a percentage of my portfolio than I would like .
If I buy anymore TEK are going to have to give me a space in company car park.
Hope TEK repay our faith in them, with some good news shortly .
Have a good weekend all
You were clearly right on the 10p camkite.
I get the time pressured nature of the raise but you would have thought that preliminary negotiations with institutional investors could have been carried out In advance of official FDA clearance as management must have Known the high probability of clearance.
The fact that it was over subscribed is in part indicative of the give away.
1/3 off the SP .....disappointing
Expected the dilution but 10p? Galling to say it was over subscribed , not surprised at that price!
10p Does feel like a kick in the teeth but will reserve overall judgement until we see the belluscura valuation (and what our increased share translates to).
Additionally , while the 10p placing does sting , big picture if TEK is ever going to convert potential into revenue , it needs funds and in absolute terms £3.8m is immaterial (not to our market cap but to the markets TEK are trying to penetrate ).
Awaiting further news.
GLA
‘I’m hoping the SP will drop further so I can top up!’ Really??!!
...........................................................................................................................................................................
TEK trades at a discount relative to net asset values. This reflects in part the subjectivity of these balance sheet valuations (and uncertainty regarding future earnings).
The FDA approval lends a higher degree of credibility to the value of the portfolio assets.
So all other things being equal, why wouldn't you buy if you think the SP is diverging (decreasing) relative to the true fundamental company value (which includes projection of future earnings)?
So while not my comment (regarding wanting the SP to drop) I don't find it stupid, for investors looking for value.
Buying based on the value of the company relative to the SP is the sensible approach.....unless you want to follow the stampeding herd in every direction.
Without wishing to dig people out (I really do wish everybody the best with their strategy) I find the posts relating to personal disappointment/instincts more laughable.
GLA
Excellent progress from Belluscura. Hugely important stepping stone in the journey of this portfolio.
Muted response in the SP (currently) . Definitely some profit taking going on. You only have to look at the 52 week SP range, to know that the SP is not a wholly rational reflection of the fundamentals of TEK.
Time to push forwards on all fronts. Keep the progress and news coming . Well done TEK!
To the best of my knowledge the current expenses for TEK outstrip revenue. Hence , my comments regarding loss making. Would be great to get some updated sales figures.
You are entirely correct , that TEK did record a profit in the accounts due an adjustment in the valuation of investments .....adjustments like that never fill me with much confidence (I don’t know the underlying detail behind the re-valuation).
The crowd funding/dilution is reflective of lack of revenue as would be expected of companies in their infancy looking to upscale .
Hopefully concrete progress soon
GLA
Very good D.monies :-) :-)
While I am surprised anybody can be bothered to ascertain where and when I post.....
Perhaps, for the sake of balance, it is worth mentioning I rarely reference Lucyd (not even in my latest post - not a coincidence) as have posted numerous times I don't rate it. Also, I posted only recently I was disappointed in the Salarius sales figures.
I am entitled express a long term view. An unlike others on here , have not accused others of chasing "rainbows". It seems you are quite delicate if you delving into the world of implication from my waffle.
Nor, have I made any references to '10 bagging' by date X.
But, you are right in that I don't say negative things about the Gross family. I would not comment negatively about anybody family (or anybody) with out the information to justify doing so.
I also frequently highlight the risk of investment in my posts. I spend all day assessing financial risk (when not looking at the Charlton athletic website in dismay) .......but not for TEK :-)
Have a good weekend d.monies and all
Good afternoon,
Everybody here, whatever their entry point, has knowingly invested in a company that is not currently profitable.
Not currently profitable means share dilution is almost inevitable. Dilution is a consideration at the outset when investing in any AIM company. Not particular to TEK.
Despite the dilution the share price , for the moment at least, the is holding up relatively well. No not if you invested at 50p! !! But, if you invested at 50p, you have to do your own appraisal of whether the assets of the company were worth you paying 50p at that time?
Many concerns on here are valid. How can anybody not have valid concerns about a company that is not self sustaining (burning money)? I certainly do.
Given we have all invested in a loss making business, presumably everybody here is looking for tomorrows winner.
Frustration seems to relate to the definition of tomorrow and whether tomorrow will actually arrive (not helped by overly optimistic announcement by TEK in relation to Belluscura). Natural concerns.
I am all for asking questions and for updates/ explanations with regard to progress (Salarius, Belluscura, Guident). I want news of concrete progress. Where I differ, is the drawing of straight lines, from TEK is not financially successful (yet), to the following unsubstantiated claims and criticism on this board:
The board is not motivated - subjective / unfounded
The board is not showing any urgency, don't appreciate it is a private venture - subjective / unfounded
Manzanilla is not doing a good job - subjective (definitely not produced good sales figures, yet!)
Criticism of employing family members (perhaps they are the best person for the job, more skin in the game from a reputational perspective)
Belluscura is dead - Subjective. Could be correct but based on current known information is more emotional/frustration than rational.
Every single one of these is these claims is unsubstantiated and alternative explanation / interpretation could be produced.
If you were a new investor looking at this board you would think 'run for the hills'.
When in fact, we have a leadership team full of integrity and intellectual capability. Cliff seems engaged and excited when he speaks about TEK.
TEK has a portfolio of quality products which as yet have not made a financial break through. This represents an opportunity (and a risk) from an investment perspective.
AIM is about the winner of tomorrow and TEK has much more potential than most to be a big winner.
If it stays at this level (or lower), when the tax year changes in little over a months time, I will happily invest some more as part of a diversified portfolio.
Have a good weekend (and break from fixating on the daily SP)
GLA
Hi Seaman, in terms of saying ‘news soon’, this is not my subjective opinion. The FDA will grant or decline approval imminently. It is with the FDA (the assessment process cannot go on indefinitely).
Hi d.Monies . Salarius and Lucyd have been brought to market ....if belluscura is approved , that will be the third portfolio brought from concept to commercial reality. There is uncertainty of future success (none of the portfolios have had a break through in terms of financial success) .
I have faith in the integrity of the management , not that this guarantees success. You seem to be suggesting otherwise , with the ‘suspect’ reference. I can’t imagine holding my investment in those circumstances, even if selling at a loss .
Good luck all
It not rational to say belluscura is a dead duck based on the current delay.
The share price will be +50% (that’s very conservative) if approval granted.
Hard for any sensible investor to dismiss this potential increase as meaningless.
The product is with FDA and so until there is news to the contrary, further delays would seem to be
out of belluscura’s Control.
It is only a dead duck if you think it will never get FDA approval or if given approval, you think it won’t be able to successfully penetrate the market. FDA approval is more likely than not and even if they can’t penetrate the market , the intellectual property has value.
As is often the case on here , missed dead lines are referred to as something that relates to pure incompetence. In my personal view, this is to misunderstand the nature of technological development. There are delays and bumps in the road when producing new technology / products.
When producing anything new , there is always an unknown element in terms of time .
You can’t directly compare it to the more structured delivery time table than may be more relevant to other products and sectors . In my personal experience, I have seen millions spent on IT Infrastructure , only for those projects to be abandoned totally (by large blue chip companies - after years of development ).
TEK May have been overly optimistic in the past in terms of delivery dates . But , as investors, what is the sense in criticising announcements made in 2018? The SP is a reflection of the here and now not 2018. The current SP reflects missed dead lines and lack of news .
As is always the case with start ups , there is uncertainty around every corner. But, in terms of belluscura we should know very soon. I would suggest a prospective evaluation is the way forward (not revisiting historical failures - unless you genuinely believe these failures are indicative of the future - in which case why are you invested here ?)
GLA
The key difference now relative to the past, is that to the best of our knowledge, the FDA now has everything it needs to give clearance (or not). Assuming no more debacles (not enough units provided etc).
For the moment, the time scale for delivery is in the hands of the FDA and not TEK. Good probability of clearance IMHO.
The crowd funding presentation shows salarius is not generating any significant income.
It is disappointing that salarius is not yet generating substantial revenue (I had hoped there would be more progress) but I still have strong belief in the long terms prospects of this product. Patience is warranted. No amount of technical analysis of the balance sheet will tell you if this product is going to be successful, so yes, it will come down to speculation and an appraisal of the strength/potential of the product. And a long term view as is always the case with TEK.
It remains the only true “salt” (sodium chloride) low sodium alternative. All (known ) competing low sodium alternatives contain potassium, which is said to to impair the taste. So in theory salarius currently has a distinct advantage in this respect.
There is an ever increasing focus on healthy food and particularly the unhealthy nature of processed foods (and snacks). There are lots of different artificial sweetners. But, there is a huge gap in the global market for a low sodium alternative.
Salarius are burning cash at the moment. This is of course a legitimate concern but hopefully two big positives will be realised as a result of the inwards investment.
Firstly, the possible improved offering with 80% reduced sodium but the same taste . The current product has 50% reduced sodium. This improved offering could tip the scales terms of landing a large contract. Let’s see if salarius can bring this market. Exciting potential.
Secondly, money has been invested in enhancing the ability to upscale production. Could do with some more detail on that point but still important progress. There are long term the plans to distribute to Asia, another massive market.
We were told at the AGM that 20 large companies were carrying out an assessment of salarius. It would be interesting to know what has come of those dealings? This is a big unknown.
Vague reference is made to being in talks with other companies in the crowd funding presentation. Cliff did say that these things move slowly, given any change in key ingredients requires intensive consumer testing. I believe in the product but would like to know if any of those 20 companies are still involved with salarius.
The 18 chain restaurant deal sounds relatively minor . Hopefully it will lead to bigger things . It is worth remembering, that the COVID has disrupted the normal trade of restaurants (this applies more to the US than Mexico I believe). Which may contribute to delays in the adoption of salarius in this sector.
The potential very much exists for salarius to make a break through. Let’s hope they can realise that potential .
There are many twists and turns ahead in the journey of TEK.
Good luck all